Unicycive terminates ATM equity offering agreement with JonesTrading, effective Jan 8, 2023

Unicycive Therapeutics, Inc.

Terminated ATM equity offering with JonesTrading effective Jan 8, 2023; no sales since Dec 15, 2022.
Originally announced Aug 15, 2022; allowed sales of up to $3M of common stock.
Company cited limiting uncertainty and unfavorable dilution for shareholders as reason.
No termination penalties; no further obligations after effective date.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Unicycive Therapeutics, Inc. terminated Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (effective 2023-01-08).

Action: termination
Agreement: atm program
Counterparty: JonesTrading Institutional Services LLC
Effective: 2023-01-08

Exact text from the filing

On December 29, 2022, Unicycive Therapeutics, Inc. (the “Company”), provided notice of its termination, effective January 8, 2023, of the Capital on Demand Sales AgreementTM, dated as of August 15, 2022 (the “Sales Agreement”), by and between the Company and JonesTrading Institutional Services LLC (“JonesTrading”).

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-083446

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.